Hengrui pharmaceutical will usher in a new drug harvest period in the next three years

Dai Hongbin, Secretary of the board of directors of Hengrui pharmaceutical, said that in the next three years, innovative drugs apatinib, famitinib, long-term CSF of biological innovative drugs, and a number of heavy weight generic drugs will be listed in a centralized way, and the company will usher in the second peak of performance growth after listing At present, Hengrui pharmaceutical is in a breakthrough stage from imitated medicine to innovative medicine, from chemical medicine to biological medicine, from domestic market to international market "In the future, the company will rely on three main lines of development, namely, high-end generic import substitution, innovative drug research and development, and preparation export." About the company The low performance has gone "the fundamentals of the company almost bottomed out in 2013." In the view of Xiang Jun, an analyst at Societe Generale Securities pharmaceutical, this is a year of "pitfall" Many adverse factors have come to our face: the main varieties of anti-tumor drugs have been cut down by the administration of the national development and Reform Commission, the prices of oxaliplatin in many provinces have been reduced, the process of listing innovative drugs has been delayed, the approval of generic drugs has been less, anti-commercial bribery, medical insurance control fees "Whether it's performance growth or new product approval, the fundamentals of the company are at the bottom." As a benchmark enterprise of domestic chemical medicine, Hengrui pharmaceutical's stock price has been flat in recent years Insiders explained that in recent years, the company's performance growth is not fast, mainly due to three reasons: first, the product line echelon appears fault, new generic drugs are less approved; second, the progress of innovative drugs listing is lower than expected; third, the growth of old products slows down, and the price maintenance pressure is great In the face of the operating difficulties in recent years, Hengrui pharmaceutical has made adjustments to the company's strategy The first is the new strategy of "attaching equal importance to imitation and innovation" A number of large varieties of innovative drugs, such as apatinib, famitinib and long-term CSF, are entering the harvest period Dozens of generic drugs will also be listed one after another, and a number of new products are ready to be launched The second is to actively maintain the pricing power of old products Many of the company's main varieties have passed the European and American certification, on the one hand, to expand new space for the growth of old products, on the other hand On the one hand, it can also maintain the price system of old products Xiang Jun believes that the problems such as product line, growth space and pricing power that hinder the development of Hengrui medicine have been gradually solved After the company gave up the one legged walking strategy of innovative medicine, the product line has gradually become full According to the company, there are as many as 70 varieties under research in the past 2-3 years, including more than 20 class 1 new drugs, nearly 30 class 3 new drugs and nearly 20 class 6 generic drugs In addition to the traditional advantages of tumor, anesthesia, angiography and other fields, the product line has been expanded to diabetes, cardiovascular, super antibiotics, blood system and other potential major diseases "From 2014, the company will usher in the centralized harvest period of new products It is expected that more than four varieties will be approved every year in the next five years." Said the insider.